99mTc—MDP骨扫描和肿瘤标记物对非小细胞肺癌分期诊断的价值

目的：研究^99mTc—MDP骨扫描和肿瘤标记物在非小细胞肺癌分期诊断中的价值。方法：对156例初诊非小细胞肺癌患者行99mTc—MDP骨扫描，并收集肺癌患者和30例正常人的．血清标本，用化学发光法检测CEA、CA125、NSE和CYFRA21—1四项指标。结果：病人CEA、CA125、NSE和CYFRA21—1高于正常人（P〈0．01），并且随着期别进展，肿瘤标记物水平逐步升高。^99mTc—MDP骨扫描明确骨转移的占25．64％（40／156），Ⅳ期81例患者48．12％（39／81）发生骨转移。结论：^99mTc—MDP核素骨扫描可作为肺癌分期检查的筛查手段；随着肺癌病程的进展，肿瘤标记物CEA、CA125、NSE和CYFRA21—1的水平逐渐上升,^99mTc—MDP骨扫描联合肿瘤标记物在非小细胞肺癌分期诊断中具有重要的价值。

The value of combination 99mTC - MDP bone scanning with serum tumor marker measurement in the stages of non -small lung cancer

Objective： To study the value of combination 99mTc - MDP bone scanning with serum tumor marker measurement in the stages of patients with non - small lung cancer. Methods： 99mTc - MDP whole - body bone scan- ning was performed in 156 patients with non - small lung cancer, the serum samples were collected in 156 patients and 30 comparison controls. CEA, CA125, NSE and CYFRA21 -1 were measured by chemiluminescence technique. Results： In 156 patients with non- small lung cancer, Ⅰ stage patients were 6. 41% （ 10/156 ） , Ⅱ stage patients 5.77% （9/156）, Ⅲ stage patients 15.38% （24/156）, Ⅳ stage patients 51.92% （81/156） ,unknowable stage patients 20.51% （32/156）. The average value of CEA and CYFRA21 - 1 in I stage patients was higher than the control group（ P 〈 0.05 ）. CEA, CA125, NSE and CYFRA21 -1 inⅡ stage patients was higher than the control group （P 〈 0.01 ）. Following the stage advancement the revel of these serum tumor marker was higher and higher. The positive ratio of patietens with osseous metastasis was confirmed by 99mTc - MDP whole - body bone scanning was 25.64% （40/156）, 48.12% （39/82） patients osseous metastasized in 82 IV stage patients. Conclusion： 99mTc- MDP bone scanning was considerable in the stages of lung cancer, following the stage advancement CEA, CA125, NSE and CY- FRA21 - 1 was higher and higher. Combination 99mTc - MDP bone scanning with serum tumor marker measurement are valuable to the stage diagnosis of non - small lung cancer.